About the Company
We do not have any company description for Ocugen, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Ocugen, Inc.
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness ...
Ocugen Inc. stock rises Friday, outperforms market
Shares of Ocugen Inc. OCGN rallied 1.94% to $1.05 Friday, on what proved to be an all-around mixed trading session for the ...
Ocugen, Inc. (NASDAQ:OCGN) About To Shift From Loss To Profit
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. With t ...
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 ...
MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced ...
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of ...
MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing ...
Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript
Ocugen, Inc. (NASDAQ: OCGN) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Arun Upadhyay - Chief Scientific Officer and Head of Research & Development Huma Qamar ...
Ocugen Inc. stock falls Tuesday, underperforms market
This was the stock's second consecutive day of losses.
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for ...
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across ...
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic ...
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy ...
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
Ocugen, Inc. OCGN is likely to provide updates on its pipeline developments when it reports first-quarter 2021 results. The company has a disappointing earnings surprise history, having missed ...
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness ...
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial ...
MALVERN, Pa., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and ...
Similar Companies
Loading the latest forecasts...